These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 27726850)

  • 1. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA.
    De Visschere P; Lumen N; Ost P; Decaestecker K; Pattyn E; Villeirs G
    Clin Radiol; 2017 Jan; 72(1):23-32. PubMed ID: 27726850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer.
    Gaur S; Harmon S; Mehralivand S; Bednarova S; Calio BP; Sugano D; Sidana A; Merino MJ; Pinto PA; Wood BJ; Shih JH; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2018 Nov; 48(5):1326-1335. PubMed ID: 29603833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
    J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
    Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
    AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer.
    Hassanzadeh E; Alessandrino F; Olubiyi OI; Glazer DI; Mulkern RV; Fedorov A; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2018 May; 43(5):1237-1244. PubMed ID: 28840280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy.
    Jambor I; Kähkönen E; Taimen P; Merisaari H; Saunavaara J; Alanen K; Obsitnik B; Minn H; Lehotska V; Aronen HJ
    J Magn Reson Imaging; 2015 May; 41(5):1394-404. PubMed ID: 24956412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra- and interreader reproducibility of PI-RADSv2: A multireader study.
    Smith CP; Harmon SA; Barrett T; Bittencourt LK; Law YM; Shebel H; An JY; Czarniecki M; Mehralivand S; Coskun M; Wood BJ; Pinto PA; Shih JH; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2019 Jun; 49(6):1694-1703. PubMed ID: 30575184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen.
    Kuhl CK; Bruhn R; Krämer N; Nebelung S; Heidenreich A; Schrading S
    Radiology; 2017 Nov; 285(2):493-505. PubMed ID: 28727544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Local Recurrence of Prostate Cancer After Radical Prostatectomy Using Endorectal Coil MRI at 3 T: Addition of DWI and Dynamic Contrast Enhancement to T2-Weighted MRI.
    Kitajima K; Hartman RP; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    AJR Am J Roentgenol; 2015 Oct; 205(4):807-16. PubMed ID: 26397329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.
    Vargas HA; Hötker AM; Goldman DA; Moskowitz CS; Gondo T; Matsumoto K; Ehdaie B; Woo S; Fine SW; Reuter VE; Sala E; Hricak H
    Eur Radiol; 2016 Jun; 26(6):1606-12. PubMed ID: 26396111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
    Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
    AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: Comparison between readers with different experience.
    Di Campli E; Delli Pizzi A; Seccia B; Cianci R; d'Annibale M; Colasante A; Cinalli S; Castellan P; Navarra R; Iantorno R; Gabrielli D; Buffone A; Caulo M; Basilico R
    Eur J Radiol; 2018 Apr; 101():17-23. PubMed ID: 29571792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treatment according to PRIAS.
    Park JJ; Park BK
    J Magn Reson Imaging; 2017 Jun; 45(6):1753-1759. PubMed ID: 27783436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance and reproducibility of T2w based and diffusion weighted imaging (DWI) based PI-RADSv2 lexicon descriptors for prostate MRI.
    Benndorf M; Hahn F; Krönig M; Jilg CA; Krauss T; Langer M; Dovi-Akué P
    Eur J Radiol; 2017 Aug; 93():9-15. PubMed ID: 28668436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.
    Vilanova JC; Barceló-Vidal C; Comet J; Boada M; Barceló J; Ferrer J; Albanell J
    AJR Am J Roentgenol; 2011 Jun; 196(6):W715-22. PubMed ID: 21606259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the prostate imaging reporting and data system for the detection of prostate cancer by the results of targeted biopsy of the prostate.
    Baur AD; Maxeiner A; Franiel T; Kilic E; Huppertz A; Schwenke C; Hamm B; Durmus T
    Invest Radiol; 2014 Jun; 49(6):411-20. PubMed ID: 24598440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer.
    Seo JW; Shin SJ; Taik Oh Y; Jung DC; Cho NH; Choi YD; Park SY
    AJR Am J Roentgenol; 2017 Jul; 209(1):W1-W9. PubMed ID: 28418690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility artifacts and PIRADS 3 lesions in prostatic MRI: how often is the dynamic contrast-enhance sequence necessary?
    Antunes N; Vas D; Sebastia C; Salvador R; Ribal MJ; Nicolau C
    Abdom Radiol (NY); 2021 Jul; 46(7):3401-3409. PubMed ID: 33683430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of quantitative diffusion-weighted and dynamic contrast-enhanced MRI parameters with prognostic factors in prostate cancer.
    Chung MP; Margolis D; Mesko S; Wang J; Kupelian P; Kamrava M
    J Med Imaging Radiat Oncol; 2014 Oct; 58(5):588-94. PubMed ID: 25196228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.